To access the SPUR™ research website, click here

We are pleased to announce the very satisfactory interim results of a first study conducted in the United Kingdom, which demonstrate the validity of our SPUR™ tool as a new measure of compliance in type 2 diabetes patients.

These results have been published in "The International Journal of Pharmacy Practice" and were presented at the Health Services Research and Pharmacy Practice (HSRPP) online conference.

Read the scientific publication 

Further studies to refine the structure of the SPUR™ tool and to validate its ability to predict non-adherence and its dimensions are currently underway in the United States and France that will complement these data.

Study objective and methodology

An evaluation of adherence using questionnaires filled out directly by patients (PROMs) is subject to significant variability. Indeed, depending on the measurement tool used, only one or two factors are taken into account in medication adherence. It is therefore necessary to find a way to measure adherence in a more global and precise manner.

This is the purpose of the development of our SPUR™ tool, which takes into account a large number of behavioral levers of adherence, grouped into 4 categories: 

- Social (S): how relationships with others impact behavior

- Psychological (P): psychological factors directly influencing behavior

- Usage (U): ability to access and follow treatment

- Rationale (R): cognitive and educational elements

As part of our academic research program, a cross-sectional study was conducted in the United Kingdom to assess the validity of SPUR™ as a new holistic tool for measuring medication adherence in patients with type 2 diabetes (T2D).

The objective of the study was to compare SPUR™ to previously validated PROMs and to the Medication Possession Ratio (MPR), one of the gold standard measures of adherence. Glycated hemoglobin (HbA1c), a medium-term marker of adherence in diabetic patients, was also measured to compare it to adherence assessed by our new tool.

149 patients on anti-diabetic drugs for at least 6 months were interviewed in pharmacies and hospitals. Their socio-demographic, clinical and HbA1c data were collected and they answered the SPUR™, MARS-10, BeMQ-General and BeMQ-Specific questionnaires.

Beyond compliance, a complete behavioral diagnostic tool

In addition to assessing adherence, SPUR™ provides a comprehensive understanding and management of the patient:

- By calculating the level of support required for each patient, both emotionally and practically.

- By specifying the patient's behavioral profile in order to understand the reasons for non-adherence and the behavioral levers to be activated.

- By automatically sending textual feedbacks to the patient according to his answers, allowing him to feel understood and recognized and to take a step back on his own behaviors in order to modify them.

- By also sending feedbacks to the health professional to guide him in his approach of encouraging his patient.

SPUR™ is therefore more than a new PROM. It is a real behavioral diagnostic tool that will allow to enrich and personalize patient support programs to help them manage their disease.

Please fill in the form to download our poster :

Name *

Surname *

Entreprise *

E-mail *

* I agree with Observia's GDPR

We are processing this data per your request only. We are hosting the data internally. We will not share it.

This data will be used to send you the requested content and other types of content on related topics and will be kept for a maximum of 3 years.

Here’s a link to our privacy policy. You can find out how to send a request to access your data, request to delete your data, correct any inaccuracies or restrict our processing of your data.

You have the right to lodge a complaint about the way we handle your data with French Data Protection authority CNIL or you can contact our DPO at contact form for more information or with concerns.

Download

Website